New insulin report highlights how incentives benefit middlemen, harm patients
By Brian Newell | January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Key facts: The final rebate rule will be a positive change for patients
By Tom Wilbur | January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a...
Read More
ICYMI: Cancer death rate continues decline due to advances in treatment
By Andrew Powaleny | January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...
Read More
Research shows gene therapies can offer cost savings potential of up to $1.8M over five years for patients with certain blood diseases
By Katie Koziara | January 15, 2021
A recent analysis by Health Advances looks at two particularly burdensome hematological (or blood) diseases — beta thalassemia and hemophilia A — and finds that potential gene therapies in the...
Read More
New data show retail medicine prices fell in 2019
By Katie Koziara | January 13, 2021
In 2019, retail prescription medicine prices declined by 0.4%, on average, according to National Health Expenditures (NHE) data from the Centers for Medicare & Medicaid Services (CMS) published...
Read More
Paper finds gaps in health data are a barrier to health equity
By Emily Donaldson | January 11, 2021
COVID-19 has laid bare racial disparities in the United States health system. For example, COVID-19 cases among Native Hawaiian / Pacific Islanders are up to 2.5 times higher as compared to...
Read More
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
By Jackie McRae | January 8, 2021
As part of PhRMA’s continuing work to address health inequities, we are partnering with researchers to study hotspots of COVID-19 and chronic disease inequities in New York state. Reports this...
Read More
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
By Nicole Longo | December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...
Read More
End of year Part D reading List
By Tom Wilbur | December 18, 2020
Happy Holidays, Part D readers, and thank you for following along this year as we explored the impact of Medicare Part D and the important role the program plays for seniors and those with...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
